Epion Therapeutics

About:

Epion is developing a minimally invasive treatment for an ectatic corneal disease.

Website: https://www.epiontx.com

Top Investors: Global Health Investment Fund (GHIF)

Description:

Epion is developing a minimally invasive treatment for an ectatic corneal disease that can bring early intervention to millions of patients globally. Their EpiSmart approach is a transformative cross-linking system designed to treat keratoconus without disrupting the epithelium, allowing for a rapid return to normal activities. Epion was founded and is supported by experts in the field, including Michael W. Belin, MD, Chief Medical Officer, who developed the Belin ABCD Progression Display, which is able to identify keratoconus progression earlier than previously relied upon metrics.

Total Funding Amount:

$32M

Headquarters Location:

Burlington, Massachusetts, United States

Founded Date:

2012-01-01

Contact Email:

info(AT)epiontx.com

Founders:

Roy Rubinfeld

Number of Employees:

1-10

Last Funding Date:

2022-09-30

IPO Status:

Private

Industries:

© 2025 bioDAO.ai